Company Overview and News


Add DVAX
to your dashboard

Headline News

Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer

2017-11-15 zacks
With just a handful of biotech companies left to report third quarter results, focus is back on regulatory and pipeline updates. Among major news this week, Dynavax Technologies (DVAX - Free Report) finally gained FDA approval for its hepatitis B vaccine while Loxo Oncology (LOXO - Free Report) was in the news for its collaboration agreement with Bayer. Recap of the Week’s Most Important Stories Loxo down despite Bayer Deal worth Up To $1. (226-0)

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)

Dynavax Triumphs With Heplisav-B: Now What?

2017-11-10 seekingalpha
There will be no restrictive label; label will show Heplisav-B’s superior efficacy to market leader, Engerix-B. (279-1)

UPDATE 1-UK Stocks-Factors to watch on Nov 10

2017-11-10 reuters
Nov 10 (Reuters) - Britain’s FTSE 100 index is seen opening 13 points higher at 7,497 on Friday, according to financial bookmakers, with futures up 0.11 percent ahead of the cash market open. (55-1)

Dynvax Reaches The Final Point On Its Journey: FDA Approval Achieved For Hepatitis B Vaccine

2017-11-10 seekingalpha
HEPLISAV-B was shown to be superior to ENGERIX-B in a late-stage study with over 6,000 patients. (42-1)

Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up

2017-11-09 channelnewsasia
REUTERS: Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug. (42-0)

Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults

2017-11-09 marketwired
BERKELEY, CA--(Marketwired - November 09, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults. (54-1)

The Digital Disruption - Cramer's Mad Money (11/7/17)

2017-11-08 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday, November 7. (316-0)

The Zacks Analyst Blog Highlights: Royal Caribbean, Macy's, Exxon Mobil, Intel and Mastercard

2017-11-07 zacks
Chicago, IL – November 7, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Royal Caribbean (RCL - Free Report) , Macy’s (M - Free Report) , Exxon Mobil (XOM - Free Report) , Intel (INTC - Free Report) and Mastercard (MA - Free Report) . (242-0)

The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP

2017-11-07 zacks
Chicago, IL – November 7, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Facebook (FB - Free Report) , Celgene (CELG - Free Report) , BlackRock (BLK - Free Report) , Danaher (DHR - Free Report) and BP (BP - Free Report) . (288-0)

The Zacks Analyst Blog Highlights: Groupon, LSI Industries, Glu Mobile, Tesco and LimeLight Networks

2017-11-07 zacks
Chicago, IL – November 7, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Groupon, Inc. (GRPN - Free Report) , LSI Industries Inc. (LYTS - Free Report) , Glu Mobile Inc. (GLUU - Free Report) , Tesco PLC (TSCDY - Free Report) and LimeLight Networks, Inc. (181-0)

Zacks Industry Outlook Highlights: Oil & Gas, including ExxonMobil, Chevron, Royal Dutch Shell, BP and TOTAL

2017-11-07 zacks
Chicago, IL – November 7, 2017 – Today, Zacks Equity Research discusses the Oil & Gas, including ExxonMobil (XOM - Free Report) , Chevron (CVX - Free Report) , Royal Dutch Shell’s (RDS.A - Free Report) , BP plc (BP - Free Report) and TOTAL (TOT - Free Report) . (204-0)

Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning

2017-11-07 zacks
Chicago, IL – November 7, 2017 - Stocks in this week’s article PetMed Express Inc. (PETS - Free Report) , Microsoft Corporation (MSFT - Free Report) , Rockwell Collins, Inc. (COL - Free Report) , Jones Lang LaSalle Incorporated (JLL - Free Report) and Owens Corning Inc. (OC - Free Report) . (196-0)

Zacks.com featured highlights: WellCare Health Plans, Boston Beer Company, Adobe Systems and Take Two Interactive Software

2017-11-07 zacks
Chicago, IL – November 7, 2017 - Stocks in this week’s article WellCare Health Plans Inc. (WCG - Free Report) , Boston Beer Company Inc. (SAM - Free Report) , Adobe Systems Inc. (ADBE - Free Report) and Take Two Interactive Software Inc (TTWO - Free Report) . (210-0)

Zacks.com featured highlights: Micron Technology, Vishay Intertechnology, Coherent, Lam Research and Ferro

2017-11-07 zacks
Chicago, IL – November 7, 2017 - Stocks in this week’s article Micron Technology, Inc. (MU - Free Report) , Vishay Intertechnology Inc. (VSH - Free Report) , Coherent Inc. (COHR - Free Report) , Lam Research Corporation (LRCX - Free Report) and Ferro Corporation (FOE - Free Report) . (282-0)

Stock Research Report

Dynavax Technologies is a clinical-stage immunotherapy company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (“TLR”) stimulation. Dynavax current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist that was selected for characteristics optimal for treatment of cancer, including high interferon induction. Directly injecting SD-101 into a tumor site optimizes its effect by ensuring proximity to tumor-specific antigens. In animal models, SD-101 demonstrated significant anti-tumor effects at both the injected site and at distant sites. Dynavax is conducting a clinical program intended to assess potential efficacy of SD-101 in a range of tumors and in combination with a range of treatments, including checkpoint inhibitors and...

Click for full article
CUSIP: 268158201